In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.
Bristol-Myers Squibb (NYSE:BMY) has announced it will be divesting itself of its joint diabetes franchise that it held with AstraZeneca (NYSE:AZN), selling its portion back to AZN for $2.7 billion, plus a milestone payment of $700 million if the sodium-glucose transport protein SGLT2 drug Forxega, focused on the treatment of diabetes, is approved. David discusses the likelihood of Forxega approval, and what this could mean both for Bristol-Myers Squibb, and for AstraZeneca, as well as why it is important as an investor to be thinking long-term about Bristol-Myers when looking at this deal today.
David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.